Drug Type Small molecule drug |
Synonyms KB-0742 |
Target |
Action inhibitors |
Mechanism CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H25N5 |
InChIKeyVYKCLMALANGCDF-STQMWFEESA-N |
CAS Registry2416873-83-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Burkitt Lymphoma | Phase 2 | United States | 08 Feb 2021 | |
Burkitt Lymphoma | Phase 2 | Spain | 08 Feb 2021 | |
Burkitt Lymphoma | Phase 2 | United Kingdom | 08 Feb 2021 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | United States | 08 Feb 2021 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | Spain | 08 Feb 2021 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | United Kingdom | 08 Feb 2021 | |
Non-Hodgkin Lymphoma | Phase 2 | United States | 08 Feb 2021 | |
Non-Hodgkin Lymphoma | Phase 2 | Spain | 08 Feb 2021 | |
Non-Hodgkin Lymphoma | Phase 2 | United Kingdom | 08 Feb 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | United States | 08 Feb 2021 |
Phase 1/2 | Advanced Malignant Solid Neoplasm TFF positive | MYC amplification/overexpression | 112 | wgkfvzixdy(vtjqndpyfd) = >15% of patients include nausea, vomiting, anemia, fatigue, diarrhea, and constipation zjectwxejs (uyvjqsoglt ) | Positive | 24 May 2024 | ||
Phase 1/2 | 28 | qjcbnyzzcz(jydnwpqhey) = no grade 3/4 neutropenia observed frfbvkfxbg (xmdrkseehf ) View more | Positive | 13 Oct 2023 |